Improvement of Atopic Dermatitis After Discontinuation of Topical Corticosteroid Treatment

2000 ◽  
Vol 136 (5) ◽  
pp. 679-680 ◽  
Author(s):  
M. Fukaya
Keyword(s):  
Atopic Dermatitis ◽  
Topical Corticosteroid ◽  
Corticosteroid Treatment

Antimicrobial Silk Clothing in the Treatment of Atopic Dermatitis Proves Comparable to Topical Corticosteroid Treatment

Dermatology ◽  
2006 ◽  
Vol 213 (3) ◽  
pp. 228-233 ◽  
Author(s):  
G. Senti ◽  
L.S. Steinmann ◽  
B. Fischer ◽  
R. Kurmann ◽  
T. Storni ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Topical Corticosteroid ◽  
Corticosteroid Treatment

Protein-losing enteropathy in an infant with severe atopic dermatitis

2021 ◽  
Vol 14 (4) ◽  
pp. e241057
Author(s):  
Yuji Fujita ◽  
Kohei Nomura ◽  
Shigemi Yoshihara
Keyword(s):  
Atopic Dermatitis ◽  
Serum Albumin ◽  
Topical Corticosteroid ◽  
Urine Volume ◽  
Male Infant ◽  
Corticosteroid Treatment ◽  
Severe Atopic Dermatitis ◽  
Protein Losing Enteropathy ◽  
Protein Levels ◽  
Recurrent Vomiting

Severe atopic dermatitis (AD) may lead to various complications such as hypoproteinaemia. We describe the case of a 7-month-old male infant with severe AD complicated with protein-losing enteropathy (PLE). He was diagnosed with AD at 2 months of age; however, because of familial steroid phobia, topical corticosteroids were not administered. At 7 months of age, he was admitted to our hospital for decreased feeding, diarrhoea, reduced urine volume and recurrent vomiting. Class 3 topical corticosteroid treatment was initiated. On day 3, eczema had almost resolved. However, serum protein levels had not improved; oliguria persisted and oedema worsened. Serum albumin scintigraphy revealed radioisotopes in the distal duodenum, leading to PLE diagnosis. Systemic prednisolone and albumin were administered, with no PLE relapse after discontinuation. To our knowledge, only two infant PLE cases associated with AD were reported to date. PLE should be considered in patients with severe AD and persistent hypoproteinaemia.

scholarly journals Interleukin-8 Levels in the Stratum Corneum as a Biomarker for Monitoring Therapeutic Effect in Atopic Dermatitis Patients

2021 ◽  
pp. 1-15
Author(s):  
Susumu Murata ◽  
Sakae Kaneko ◽  
Eishin Morita
Keyword(s):  
Atopic Dermatitis ◽  
Topical Corticosteroid ◽  
Stratum Corneum ◽  
Corticosteroid Treatment ◽  
Skin Inflammation ◽  
Interleukin 8 ◽  
Tape Stripping ◽  
Therapeutic Effects ◽  
Local Skin ◽  
Before And After

<b><i>Introduction:</i></b> The stratum corneum contains several growth factors and cytokines that are synthesized in keratinocytes. We previously reported that the amount of interleukin-8 in the stratum corneum (scIL-8) is related to the severity of local skin inflammation in atopic dermatitis (AD). However, it is unknown whether scIL-8 levels reflect pharmacologic responses to a therapeutic intervention in AD patients. Therefore, in this study, we aimed to investigate whether the improvement of dermatitis in AD is correlated with scIL-8 levels before and after topical corticosteroid treatment. <b><i>Methods:</i></b> Stratum corneum samples were collected from 22 AD patients using the noninvasive tape-stripping method before treatment, 2 weeks after topical treatment, and 4–6 weeks after treatment. <b><i>Results:</i></b> scIL-8 levels on the forearm reduced significantly from 790 ± 348 pg/mg before treatment to 163 ± 68 pg/mg 2 weeks after treatment and 100 ± 37 pg/mg 4–6 weeks after corticosteroid treatment. scIL-8 levels on the abdomen also reduced significantly from 902 ± 391 to 142 ± 38 pg/mg at the end of study. The reduction in scIL-8 levels was associated with the improvement in local skin severity in AD. We also found that scIL-8 levels, along with blood biomarker levels (serum thymus and activation-regulated chemokine, lactate dehydrogenase, and %eosinophil), decreased significantly after the treatment. <b><i>Conclusion:</i></b> The scIL-8 concentration decreases with improvements in skin symptoms in AD patients after topical corticosteroid treatment; thus, it may be a suitable biomarker for monitoring therapeutic effects in AD patients.

Sign in / Sign up

Export Citation Format

Share Document